Episode Details

Dr. Dino Prato discusses the crucial role of nutrition in cancer treatment, emphasizing that a truly healthy eating approach goes beyond just adding superfoods.

He highlights the importance of removing foods that sabotage the immune system, explaining how this strategy is foundational to effective cancer treatment. Understanding "food as medicine" is key to supporting the body's defenses and acting as an immune system booster.

🎯 What You’ll Learn in This Episode:
- The first foods to eliminate from an anti-cancer diet
- Why gut microbiome health is critical
- How fatty fish and olive oil reduce inflammation
- The immune role of beta-glucans from mushrooms
- Why cruciferous vegetables support detoxification
- The benefits of berries and polyphenols
- How green tea (EGCG) supports immune balance
- Why sustainable Mediterranean-style eating works long-term

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak with a care coordinator: 866-830-4576

“Cancer care isn’t just about killing cells — it’s about strengthening the terrain.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at: 

https://www.scirp.org/journal/paperinformation?paperid=132493